Literature DB >> 2338552

Guanine nucleotide effects on 8-cyclopentyl-1,3-[3H]dipropylxanthine binding to membrane-bound and solubilized A1 adenosine receptors of rat brain.

K N Klotz1, R Keil, F J Zimmer, U Schwabe.   

Abstract

The effects of guanine nucleotides on binding of 8-cyclopentyl-1,3-[3H]dipropylxanthine ([3H]DPCPX), a highly selective A1 adenosine receptor antagonist, have been investigated in rat brain membranes and solubilized A1 receptors. GTP, which induces uncoupling of receptors from guanine nucleotide binding proteins, increased binding of [3H]DPCPX in a concentration-dependent manner. The rank order of potency for different guanine nucleotides for increasing [3H]DPCPX binding was the same as for guanine nucleotide-induced inhibition of agonist binding. Therefore, a role for a guanine nucleotide binding protein, e.g., Gi, in the regulation of antagonist binding is suggested. This was confirmed by inactivation of Gi by N-ethylmaleimide (NEM) treatment of membranes, which resulted in an increase in [3H]DPCPX binding similar to that seen with addition of GTP. Kinetic and equilibrium binding studies showed that the GTP- or NEM-induced increase in antagonist binding was not caused by an affinity change of A1 receptors for [3H]DPCPX but by an increased Bmax value. Guanine nucleotides had similar effects on membrane-bound and solubilized receptors, with the effects in the solubilized system being more pronounced. In the absence of GTP, when most receptors are in a high-affinity state for agonists, only a few receptors are labeled by [3H]DPCPX. It is suggested that [3H]DPCPX binding is inhibited when receptors are coupled to Gi. Therefore, uncoupling of A1 receptors from Gi by guanine nucleotides or by inactivation of Gi with NEM results in an increased antagonist binding.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338552     DOI: 10.1111/j.1471-4159.1990.tb04902.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Authors:  Sergi Ferré; Vicent Casadó; Lakshmi A Devi; Marta Filizola; Ralf Jockers; Martin J Lohse; Graeme Milligan; Jean-Philippe Pin; Xavier Guitart
Journal:  Pharmacol Rev       Date:  2014-02-10       Impact factor: 25.468

2.  Functional coupling between A1 adenosine receptors and G-proteins in rat hippocampal membranes assessed by high-affinity GTPase activity.

Authors:  Y Odagaki; K Fuxe
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

3.  A1 adenosine receptors can occur manifesting two kinetic components of 8-cyclopentyl-1,3-[3H]dipropylxanthine ([3H]DPCPX) binding.

Authors:  V Casadó; J Mallol; R Franco; C Lluis; E I Canela
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-05       Impact factor: 3.000

4.  The binding of 1,3-[3H]-dipropyl-8-cyclopentylxanthine to adenosine A1 receptors in rat smooth muscle preparations.

Authors:  J A Peachey; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

5.  A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex.

Authors:  S P Alexander; A R Curtis; D A Kendall; S J Hill
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

6.  Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.

Authors:  C Zocchi; E Ongini; S Ferrara; P G Baraldi; S Dionisotti
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

7.  The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.

Authors:  F R Cohen; S Lazareno; N J Birdsall
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 8.  Oligomerization of G protein-coupled receptors: Still doubted?

Authors:  Sergi Ferré; Francisco Ciruela; Vicent Casadó; Leonardo Pardo
Journal:  Prog Mol Biol Transl Sci       Date:  2019-12-12       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.